The 21st century is the century of emerging economies.
Mauritius and Singapore are very good examples of this
revolution. In this piece, Mona Dawood, Head of the
Pharmaceutical Operations & Regulatory Affairs for CIDP
group, provides an in-depth analysis of the two countries in
the context of clinical research. Mauritius and Singapore
understand the importance of investing in medical and clinical
research. The main reason is that they are both exposed to
communicable and non-communicable diseases, like numerous
countries around the world, but their geographic position and
economic stability are truly what sets them apart.